Research
Hormonal
Tight glucose control (targeting 4.4-6.1 mmol/L) increases mortality in critically ill patients compared to a less strict target (less than 10 mmol/L), and optimal targets may vary based on diabetes status.
Do not use tight glucose control (targeting 4.4-6.1 mmol/L) in critically ill patients. Instead, aim for a less strict target (less than 10 mmol/L) to avoid the increased mortality risk associated with tight control. Consider individualizing targets based on diabetes status.
GoodRefutesHIGH confidence
The largest trial, NICE-SUGAR, showed increased 90-day mortality with TGC compared to a target of less than 10 mmol/L... reduced mortality was observed with blood glucose between 80 and 140 mg/dl in non-diabetic patients and 110-180 mg/dl in diabetic patients.
Why this rating
Supported by the large NICE-SUGAR trial and other RCTs.
Source
The intensive care medicine research agenda in nutrition and metabolism
Yaseen M. Arabi et al. · Intensive Care Medicine · 2017
DOI 10.1007/s00134-017-4711-6
narrative_reviewCited 209×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Early aggressive provision of full caloric and protein targets in critically ill patients provides no clinical benefit and may cause harm, whereas permissive underfeeding (restricted feeding) during the acute phase reduces ICU-acquired weakness and improves outcomes.Good
- Immune-modulating nutrition (supplementation with glutamine, arginine, omega-3 fatty acids, and antioxidants) does not improve outcomes in general critically ill patients and may increase mortality, although it may benefit specific subgroups like severe burn patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →